img

AHA 2020

Here are the most important articles of the AHA 2020 virtual Congress.

AHA 2020 | Anticoagulación post TAVI en pacientes con fibrilación auricular

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation
Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful transcatheter aortic valve replacement (TAVR) compared ...

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization
Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase ...

AHA 2020 | Ácidos grasos omega 3 sin beneficio cardiovascular y con más fibrilación auricular

AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation
Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not reduce cardiovascular events in patients with high triglycerides and low HDL. ...

AHA 2020 | EMPATROPISM: Empagliflozina en no diabéticos con insuficiencia cardíaca

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure
Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and deteriorated ejection fraction.  ...

AHA 2020 | RIVER: Rivaroxaban como alternativa a la warfarina en pacientes con fibrilación auricular y protesis mitral biológica

AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve
Rivaroxaban seems to be a reasonable alternative to warfarin in patients with atrial fibrillation and bioprosthetic mitral valve. These results arise from the RIVER Study presented at the ...

AHA 2020 | El clopidogrel resiste como la mejor opción en pacientes electivos

AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients
High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic clopidogrel do not see a benefit in protection against periprocedural ...

AHA 2020 | POLYPILL: Una sola pastilla más aspirina para tratar todo

AHA 2020 | POLYPILL: One Pill Plus Aspirin to Treat Everything
Using only one compressed tablet or pill with a fixed combination of statins, angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics significantly lowered cardiovascular risk ...

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | AFFIRM-AHF: Ferric Carboxymaltose and Fewer Hospitalizations for Cardiac Failure
Correcting iron deficiency in patients with cardiac failure might reduce the risk of new hospitalizations according to the AFFIRM-AHF published in the Lancet and presented at AHA 2020. ...

AHA 2020 | Statins: Confirmed Benefits for the Elderly
Elderly patients (>70) with high cholesterol levels have been systematically excluded from randomized studies on statins, despite their higher risk of cardiovascular events. Presented at ...

AHA 2020 | Anticoagulación post TAVI en pacientes con fibrilación auricular

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation
Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful transcatheter aortic valve replacement (TAVR) compared ...

AHA 2020 | Aumenta el alta precoz en el TAVI con un costo esperado

AHA 2020 | Rise in Early Discharge After TAVR Has the Expected Cost
As hospitalization time after a transcatheter aortic valve replacement (TAVR) is reduced, we are observing a concomitant increase in re-hospitalizations due to conduction disorders . Early ...

AHA 2020 | AFFIRM-AHF: Suplemento de hierro y menos hospitalizaciones por insuficiencia cardíaca

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization
Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase ...

AHA 2020 | El clopidogrel resiste como la mejor opción en pacientes electivos

AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients
High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic clopidogrel do not see a benefit in protection against periprocedural ...

AHA 2020 | En gran medida, las imágenes encuentran la causa de MINOCA

AHA 2020 | In Most Cases, Imaging Can Determine What Causes MINOCA
Intravascular imaging with coronary optical coherence tomography (OCT) and magnetic resonance imaging allow for the identification of the cause of heart attack in 85% of women without coronary ...

AHA 2020 | El riesgo aumenta cuando los operadores no “escuchan” al FFR

AHA 2020 | The More Operators “Listen” to FFR, the Lower the Risk
When operators decide to proceed with PCI despite a negative FFR (fairly frequent in the daily practice) outcomes at 5 years are far worse. This information comes from a large Canadian register ...

Top